Aclarion Highlights Growing Adoption of Nociscan at The London Clinic with New Physician Video
Rhea-AI Summary
Aclarion (Nasdaq: ACON) released a new physician video (April 7, 2026) featuring Mr. John Sutcliffe of The London Spine Clinic demonstrating real-world use of Nociscan to evaluate chronic low back pain.
Nearly 100 Nociscans have been performed at The London Clinic; Nociscan uses MR spectroscopy and proprietary signal processing to identify chemical biomarkers linked to disc pain. According to the company, clinical data showed up to 97% surgical success when all Nociscan-positive discs are treated, and the video signals growing physician adoption at a leading international center.
Positive
- Nearly 100 Nociscans performed at The London Clinic
- Up to 97% surgical success when all Nociscan-positive discs are treated
- Non-invasive MR spectroscopy biomarker approach for disc pain differentiation
- Physician endorsement from Lead Clinician John Sutcliffe supports clinical utility
Negative
- Adoption concentrated at a single center: ~100 scans at The London Clinic
- No financial or commercialization metrics provided to assess market impact
News Market Reaction – ACON
In the Apr 7 session, ACON gained 4.40%, reflecting a moderate positive market reaction. Argus tracked a peak move of +12.5% during that session. Argus tracked a trough of -5.9% from its starting point during tracking. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility. Trading volume was very high at 4.2x the daily average, suggesting strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 24 | Governance dispute | Negative | +10.6% | Investor called for resignation of a board member, signaling governance friction. |
| Mar 19 | Rights plan adoption | Neutral | -1.8% | Board adopted a one-year stockholder rights plan to address potential control changes. |
| Mar 19 | CEO strategy letter | Positive | -1.8% | CEO outlined 2026 priorities, Nociscan adoption goals, and cash runway into 2028. |
| Mar 17 | Conference participation | Neutral | +0.6% | Company highlighted Nociscan progress and balance sheet at the ROTH investor conference. |
| Mar 12 | Investor meetings | Neutral | -3.2% | CEO attendance at LSI USA 2026 to discuss Nociscan and meet investors and partners. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news has produced a mix of aligned and divergent moves, with some governance and strategic updates triggering price reactions that do not always match their apparent tone.
Over the past month, Aclarion has focused on governance, strategy, and visibility. A Mar 24 call for a director’s resignation was followed by a positive price move, while a Mar 19 shareholder letter outlining Nociscan growth plans, catalysts, and a strong cash runway into 2028 coincided with modest weakness. Conference participation and investor outreach on Mar 17 and Mar 12 produced relatively small reactions. Today’s Nociscan adoption update fits the ongoing commercialization narrative.
Key Terms
biomarkers medical
augmented intelligence (AI) algorithms technical
mr spectroscopy medical
lumbar spine medical
chemical biomarkers medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Video featuring Mr. John Sutcliffe, Lead Clinician at The London Spine Clinic, highlights real-world physician experience with Nociscan in clinical practice
- Nearly 100 Nociscans performed at The London Clinic, reflecting increasing utilization for evaluation of chronic low back pain
BROOMFIELD, Colo., April 07, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced the release of a new video featuring Mr. John Sutcliffe, Consultant Spinal Neurosurgeon at The London Clinic, one of the United Kingdom’s leading private hospitals. The video is available here.
With more than 30 years of experience in treating patients with all types of spinal conditions, including back and neck pain, Mr. Sutcliffe also serves as the Lead Clinician at The London Spine Clinic and is frequently referred complex spinal cases for assessment and treatment. The video highlights his experience using Nociscan to evaluate patients with chronic low back pain.
“Nociscan provides an additional layer of insight that complements traditional imaging,” said Mr. Sutcliffe. “Having more objective data can help inform clinical decisions and improve confidence when evaluating patients with chronic low back pain.”
To date, nearly 100 Nociscans have been conducted at The London Clinic. Nociscan is a non-invasive solution that helps physicians differentiate between painful and non-painful discs in the lumbar spine by leveraging MR spectroscopy and proprietary signal processing to identify chemical biomarkers associated with disc pain. The continued use of Nociscan at The London Clinic reflects sustained physician engagement and growing integration of Nociscan into routine clinical practice.
“This video offers a compelling perspective on how Nociscan is being used in day-to-day clinical practice,” said Brent Ness, Chief Executive Officer of Aclarion. “Approaching 100 scans at a leading international center like The London Clinic is an important indicator of increasing adoption and reinforces the potential for Nociscan to become a valuable tool in the evaluation of chronic low back pain.”
Chronic low back pain is a significant global healthcare challenge, affecting approximately 266 million people worldwide. When used alongside other diagnostic tools, clinical data has demonstrated up to a
For more News from Aclarion, please visit: Latest News
To find a Nociscan center, view our site map here.
For more information on Nociscan, please email: info@aclarion.com
About Aclarion, Inc.
Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan, the first, evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain, giving physicians clarity to optimize treatment strategies. For more information, please visit www.aclarion.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 about the Company’s current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as “anticipates,” “believes” and “expects” or similar expressions, are forward-looking statements. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the Company’s current plans and expectations, as well as future results of operations and financial condition. Forward-looking statements in this release include, among others, statements regarding Aclarion Highlights Growing Adoption of Nociscan at The London Clinic, and the potential benefits of our Nociscan technology. These and other risks and uncertainties are discussed more fully in our filings with the Securities and Exchange Commission. Readers are encouraged to review the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, as well as other disclosures contained in the Prospectus and subsequent filings made with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Contacts:
Kirin M. Smith
PCG Advisory, Inc.
ksmith@pcgadvisory.com
Media Contacts:
Jennie Kim
SPRIG Consulting
jennie@sprigconsulting.com
